Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Lunai Bioworks Inc.

NASDAQ: LNAI · Life Sciences · 4 alerts · CIK 1527728

Share price
$0.1648Close, Oct 29
Market cap
$830K
Shares outstanding
5.03MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Lunai Bioworks Inc. filings on SEC EDGAR ↗

5:17 PM ET 8-K
Executive Compensation

Lunai Bioworks Executive Compensation

Lunai Bioworks entered into an amended employment agreement with CEO David Weinstein, reducing his annual base salary from $400,000 to $275,000. Weinstein waived his rights to severance and accelerated vesting, and his employment term was set to end on December 28, 2026. The agreement also terminates his non-competition and non-solicitation covenants while deferring his October 2026 salary payment.

Counterparty
David Weinstein
Term
through Dec 2026
6:02 AM ET 8-K
Nasdaq/NYSE Compliance Notice

Lunai Bioworks Nasdaq/NYSE Compliance Notice

Lunai Bioworks received a Nasdaq delisting determination for failing to maintain the minimum stockholders' equity requirement of $2.5 million, reporting a deficit of over $9 million. The company has decided not to appeal the decision and will voluntarily delist its common stock from Nasdaq and deregister with the SEC to save costs.

Counterparty
Nasdaq
4:56 PM ET 10-K
Financial Results

Lunai Bioworks FY 2026 Results: Net Loss of $3.56M, Loss Narrows

Lunai Bioworks Inc. (formerly Renovaro Biosciences) is navigating a complex regulatory landscape for its AI-driven diagnostic and therapeutic platforms, including compliance with the EU AI Act and shifting US federal oversight. The company is currently advancing pre-clinical candidates RENB-DC-11 for solid tumors and BioS_831 for epilepsy, while facing significant competition from larger pharmaceutical entities.

Key figure
Net loss $3.56M
2:00 PM ET 8-K
Court & Legal Update

Lunai Bioworks Court & Legal Update

Lunai Bioworks has requested that Nasdaq immediately suspend trading of its common stock (LNAI) due to evidence of irregular trading activity uncovered during discovery in its pending litigation against Seven Points Capital LLC. The company alleges substantial short selling, locate deficiencies, and concentrated failures to deliver that may indicate the market for its shares is not fair or orderly. Nasdaq has not yet made a decision on the request, and the underlying litigation in the U.S. District Court for the District of Delaware remains ongoing.

Counterparty
Seven Points Capital LLC

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.